Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histone Deacetylase Inhibitors | 13 | 2015 | 116 | 1.700 |
Why?
|
| Histone Deacetylases | 9 | 2016 | 99 | 1.080 |
Why?
|
| Nylons | 5 | 2012 | 9 | 1.050 |
Why?
|
| Chlorambucil | 5 | 2012 | 17 | 0.970 |
Why?
|
| Vitamin K | 2 | 2013 | 14 | 0.910 |
Why?
|
| Neuroprotective Agents | 5 | 2014 | 317 | 0.850 |
Why?
|
| Histones | 6 | 2016 | 111 | 0.760 |
Why?
|
| Cell Proliferation | 8 | 2015 | 1173 | 0.650 |
Why?
|
| Quinones | 1 | 2015 | 13 | 0.530 |
Why?
|
| Disulfides | 1 | 2015 | 40 | 0.530 |
Why?
|
| Pimelic Acids | 3 | 2010 | 3 | 0.520 |
Why?
|
| Friedreich Ataxia | 3 | 2010 | 6 | 0.520 |
Why?
|
| Sulfides | 1 | 2015 | 43 | 0.520 |
Why?
|
| Silver | 1 | 2015 | 49 | 0.510 |
Why?
|
| Small Molecule Libraries | 2 | 2013 | 53 | 0.510 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 659 | 0.400 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 63 | 0.400 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2012 | 57 | 0.380 |
Why?
|
| Base Sequence | 7 | 2013 | 1015 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 1070 | 0.340 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 37 | 0.340 |
Why?
|
| Huntington Disease | 1 | 2008 | 15 | 0.340 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2007 | 103 | 0.300 |
Why?
|
| Hydroxamic Acids | 4 | 2015 | 84 | 0.300 |
Why?
|
| Repressor Proteins | 2 | 2007 | 182 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 307 | 0.280 |
Why?
|
| Bacterial Proteins | 2 | 2007 | 244 | 0.280 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 2550 | 0.240 |
Why?
|
| Retinal Degeneration | 2 | 2014 | 75 | 0.220 |
Why?
|
| Retina | 2 | 2016 | 252 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 346 | 0.220 |
Why?
|
| Mice | 13 | 2015 | 8472 | 0.220 |
Why?
|
| Pyrroles | 3 | 2012 | 83 | 0.210 |
Why?
|
| Imidazoles | 3 | 2012 | 175 | 0.210 |
Why?
|
| Chromatin | 1 | 2012 | 76 | 0.210 |
Why?
|
| Neoplasms | 3 | 2013 | 1660 | 0.190 |
Why?
|
| Reperfusion Injury | 2 | 2014 | 320 | 0.190 |
Why?
|
| Animals | 17 | 2016 | 20877 | 0.190 |
Why?
|
| Cell Line, Tumor | 6 | 2015 | 1849 | 0.190 |
Why?
|
| Peptides | 2 | 2014 | 455 | 0.170 |
Why?
|
| Structure-Activity Relationship | 3 | 2014 | 420 | 0.160 |
Why?
|
| Benzamides | 2 | 2009 | 156 | 0.160 |
Why?
|
| Caspase 3 | 2 | 2016 | 233 | 0.150 |
Why?
|
| Blotting, Western | 4 | 2016 | 954 | 0.150 |
Why?
|
| Acetylation | 4 | 2016 | 94 | 0.150 |
Why?
|
| Retinal Ganglion Cells | 2 | 2014 | 72 | 0.150 |
Why?
|
| Kinetics | 3 | 2008 | 1047 | 0.150 |
Why?
|
| Humans | 19 | 2015 | 68525 | 0.140 |
Why?
|
| Histone Deacetylase 2 | 2 | 2013 | 7 | 0.140 |
Why?
|
| Ischemic Preconditioning | 1 | 2016 | 31 | 0.140 |
Why?
|
| Neuroprotection | 1 | 2016 | 28 | 0.140 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2015 | 69 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 304 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 101 | 0.130 |
Why?
|
| DNA Primers | 2 | 2013 | 302 | 0.130 |
Why?
|
| DNA | 3 | 2009 | 597 | 0.130 |
Why?
|
| Catalysis | 1 | 2015 | 123 | 0.130 |
Why?
|
| Nitric Oxide Donors | 1 | 2015 | 54 | 0.130 |
Why?
|
| Models, Biological | 3 | 2008 | 981 | 0.120 |
Why?
|
| Electroretinography | 4 | 2016 | 122 | 0.120 |
Why?
|
| Ocular Hypertension | 1 | 2014 | 43 | 0.120 |
Why?
|
| Cardiomegaly | 1 | 2015 | 213 | 0.120 |
Why?
|
| Cell Line | 3 | 2013 | 1752 | 0.120 |
Why?
|
| Intraocular Pressure | 1 | 2014 | 143 | 0.120 |
Why?
|
| Neural Stem Cells | 1 | 2014 | 32 | 0.120 |
Why?
|
| Lysine | 1 | 2014 | 96 | 0.120 |
Why?
|
| Vitamin K 3 | 1 | 2013 | 3 | 0.120 |
Why?
|
| Laminin | 1 | 2014 | 62 | 0.120 |
Why?
|
| Molecular Structure | 1 | 2015 | 397 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1446 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2013 | 37 | 0.120 |
Why?
|
| Dimethylallyltranstransferase | 1 | 2013 | 2 | 0.120 |
Why?
|
| Vitamin K 2 | 1 | 2013 | 2 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1745 | 0.120 |
Why?
|
| Iron-Binding Proteins | 2 | 2010 | 5 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 1293 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2012 | 1663 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.110 |
Why?
|
| Histone Deacetylase 6 | 1 | 2011 | 4 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2013 | 102 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 284 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2013 | 223 | 0.100 |
Why?
|
| Mice, Nude | 2 | 2013 | 294 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 4 | 2015 | 532 | 0.100 |
Why?
|
| Drug Design | 4 | 2015 | 107 | 0.100 |
Why?
|
| Alkylation | 2 | 2008 | 26 | 0.100 |
Why?
|
| Models, Molecular | 3 | 2013 | 546 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 116 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2015 | 447 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 902 | 0.090 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2673 | 0.090 |
Why?
|
| Cell Survival | 2 | 2014 | 901 | 0.090 |
Why?
|
| Genes | 1 | 2009 | 86 | 0.090 |
Why?
|
| HeLa Cells | 3 | 2015 | 237 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2008 | 312 | 0.090 |
Why?
|
| Epilepsy | 1 | 2013 | 336 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2010 | 682 | 0.090 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2015 | 37 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2009 | 137 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 26 | 0.080 |
Why?
|
| Blood Cells | 1 | 2008 | 27 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 252 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 710 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 81 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2013 | 718 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2008 | 234 | 0.080 |
Why?
|
| Dimerization | 2 | 2007 | 99 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 217 | 0.080 |
Why?
|
| Histone Deacetylase 1 | 3 | 2015 | 32 | 0.080 |
Why?
|
| Metals | 2 | 2007 | 100 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 322 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2008 | 308 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2008 | 178 | 0.080 |
Why?
|
| Plasmids | 2 | 2006 | 258 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2015 | 562 | 0.080 |
Why?
|
| Piperazines | 1 | 2008 | 206 | 0.070 |
Why?
|
| Alkylating Agents | 1 | 2006 | 15 | 0.070 |
Why?
|
| Interphase | 1 | 2006 | 19 | 0.070 |
Why?
|
| Binding Sites | 2 | 2007 | 631 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 852 | 0.070 |
Why?
|
| Aminobutyrates | 1 | 2006 | 94 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1174 | 0.070 |
Why?
|
| src Homology Domains | 1 | 2004 | 29 | 0.060 |
Why?
|
| Nickel | 1 | 2004 | 18 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2004 | 60 | 0.060 |
Why?
|
| Rats, Inbred BN | 2 | 2014 | 51 | 0.060 |
Why?
|
| Ions | 1 | 2004 | 50 | 0.060 |
Why?
|
| Tryptophan | 1 | 2004 | 65 | 0.060 |
Why?
|
| Anisotropy | 1 | 2004 | 105 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2004 | 112 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 111 | 0.060 |
Why?
|
| U937 Cells | 2 | 2014 | 61 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2012 | 447 | 0.060 |
Why?
|
| Valproic Acid | 2 | 2014 | 93 | 0.060 |
Why?
|
| Cell Culture Techniques | 2 | 2015 | 189 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2004 | 362 | 0.060 |
Why?
|
| Iron | 1 | 2004 | 197 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2003 | 221 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 52 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2012 | 167 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2003 | 241 | 0.050 |
Why?
|
| Protein Binding | 1 | 2004 | 1027 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2012 | 326 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 2790 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 700 | 0.050 |
Why?
|
| Female | 6 | 2014 | 38015 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2015 | 1692 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 332 | 0.040 |
Why?
|
| Male | 6 | 2016 | 37281 | 0.040 |
Why?
|
| Inflammation | 1 | 2003 | 1030 | 0.040 |
Why?
|
| Rats | 2 | 2016 | 5300 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 742 | 0.040 |
Why?
|
| Obesity | 1 | 2003 | 1074 | 0.040 |
Why?
|
| YY1 Transcription Factor | 1 | 2015 | 6 | 0.030 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Time Factors | 3 | 2013 | 4655 | 0.030 |
Why?
|
| Apoptosis | 2 | 2015 | 1640 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cats | 1 | 2015 | 292 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 226 | 0.030 |
Why?
|
| Retinal Neurons | 1 | 2014 | 9 | 0.030 |
Why?
|
| Acetyltransferases | 1 | 2014 | 49 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 100 | 0.030 |
Why?
|
| Pentylenetetrazole | 1 | 2013 | 10 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.030 |
Why?
|
| Naphthoquinones | 1 | 2013 | 14 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2013 | 50 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2014 | 78 | 0.030 |
Why?
|
| Swimming | 1 | 2013 | 38 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 80 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 614 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2013 | 128 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1039 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2013 | 114 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 289 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2014 | 94 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 324 | 0.030 |
Why?
|
| Zebrafish | 1 | 2013 | 187 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 258 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 314 | 0.030 |
Why?
|
| Heart | 1 | 2015 | 850 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2009 | 15 | 0.020 |
Why?
|
| K562 Cells | 1 | 2009 | 44 | 0.020 |
Why?
|
| Photoaffinity Labels | 1 | 2009 | 7 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1329 | 0.020 |
Why?
|
| Cyclization | 1 | 2009 | 14 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 492 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 31 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 2007 | 122 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2007 | 92 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2006 | 169 | 0.020 |
Why?
|
| G2 Phase | 1 | 2006 | 26 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 190 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 150 | 0.020 |
Why?
|
| Cell Division | 1 | 2006 | 541 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 756 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 434 | 0.020 |
Why?
|
| Polymers | 1 | 2006 | 244 | 0.020 |
Why?
|
| Giant Cells | 1 | 2003 | 14 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2003 | 33 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 201 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 76 | 0.010 |
Why?
|
| Adipocytes | 1 | 2003 | 88 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2003 | 228 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 171 | 0.010 |
Why?
|
| Neutrophils | 1 | 2003 | 204 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 554 | 0.010 |
Why?
|
| Macrophages | 1 | 2003 | 647 | 0.010 |
Why?
|